What the Research Says
Myo-inositol has become one of the most evidence-based supplements for PCOS, with endorsement from the 2017 International Consensus Conference on myo-inositol and D-chiro-inositol in obstetrics and gynecology. Unfer et al. (2012) published a comprehensive meta-analysis showing significant improvements in insulin resistance, androgen levels, and ovulatory function. The 40:1 myo-inositol to D-chiro-inositol ratio, proposed by Nordio & Proietti (2012), reflects the physiological plasma ratio and has shown superior results to either isomer alone. Multiple head-to-head trials with metformin have shown comparable efficacy for insulin sensitization in PCOS with fewer side effects. The mechanism is well-understood: myo-inositol is an essential component of the insulin-signaling cascade via phosphatidylinositol 3-kinase (PI3K) pathway.
